Specialties
- Cardiology
Area of focus i
- Women and Heart Disease
- Cardio-Oncology
- Congestive Heart Failure
Affiliated with
LVPG Cliniciani
2649 Schoenersville Road
Suite 301
Bethlehem, PA 18017-7332
United States
With the increasing use of immune checkpoint inhibitors (ICI) to treat cancer, certain adverse events may occur. One of the rarer, but dangerous adverse events due to treatment with ICI treatment is myocarditis. Individuals who are diagnosed with ICI associated myocarditis have a 25-45% chance of developing a severe cardiac adverse event (heart can stop, fast heart rhythm, slow heart rhythm, or heart failure). There are no definitive treatments for ICI associated myocarditis, with only corticosteroids. In this study, the research is investigating if abatacept can be an effective and safe treatment for patients diagnosed with ICI associated myocarditis.
The purpose of the study is to evaluate whether abatacept is associated with a reduction in severe cardiac events among participants hospitalized with myocarditis secondary to taking an immune checkpoint inhibitor.
Inclusion Criteria-including but may not be limited to:
Please contact the Network Office of Research and Innovation at 610-402-9543.
https://clinicaltrials.gov/ct2/show/NCT05335928?term=ICI+myocarditis&draw=2&rank=1
LVPG Cliniciani
2649 Schoenersville Road
Suite 301
Bethlehem, PA 18017-7332
United States
LVPG Cliniciani